Evolution of a New AAV Variant with Murine T Lymphocyte Tropism Using the MHC-Ib Molecule H2-Q7 as a Receptor
Publication
, Conference
Ark, JI; Nyberg, W; Clouden, S; Havlik, PL; Eyquem, J; Asokan, A
Published in: MOLECULAR THERAPY
2022
Duke Scholars
Published In
MOLECULAR THERAPY
EISSN
1525-0024
ISSN
1525-0016
Publication Date
2022
Volume
30
Issue
4
Start / End Page
389 / 389
Related Subject Headings
- Biotechnology
- 3206 Medical biotechnology
- 3202 Clinical sciences
- 3105 Genetics
- 11 Medical and Health Sciences
- 10 Technology
- 06 Biological Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Ark, J. I., Nyberg, W., Clouden, S., Havlik, P. L., Eyquem, J., & Asokan, A. (2022). Evolution of a New AAV Variant with Murine T Lymphocyte Tropism Using the MHC-Ib Molecule H2-Q7 as a Receptor. In MOLECULAR THERAPY (Vol. 30, pp. 389–389).
Ark, Jonathan I., William Nyberg, Sylvanie Clouden, Patrick L. Havlik, Justin Eyquem, and Aravind Asokan. “Evolution of a New AAV Variant with Murine T Lymphocyte Tropism Using the MHC-Ib Molecule H2-Q7 as a Receptor.” In MOLECULAR THERAPY, 30:389–389, 2022.
Ark JI, Nyberg W, Clouden S, Havlik PL, Eyquem J, Asokan A. Evolution of a New AAV Variant with Murine T Lymphocyte Tropism Using the MHC-Ib Molecule H2-Q7 as a Receptor. In: MOLECULAR THERAPY. 2022. p. 389–389.
Ark, Jonathan I., et al. “Evolution of a New AAV Variant with Murine T Lymphocyte Tropism Using the MHC-Ib Molecule H2-Q7 as a Receptor.” MOLECULAR THERAPY, vol. 30, no. 4, 2022, pp. 389–389.
Ark JI, Nyberg W, Clouden S, Havlik PL, Eyquem J, Asokan A. Evolution of a New AAV Variant with Murine T Lymphocyte Tropism Using the MHC-Ib Molecule H2-Q7 as a Receptor. MOLECULAR THERAPY. 2022. p. 389–389.
Published In
MOLECULAR THERAPY
EISSN
1525-0024
ISSN
1525-0016
Publication Date
2022
Volume
30
Issue
4
Start / End Page
389 / 389
Related Subject Headings
- Biotechnology
- 3206 Medical biotechnology
- 3202 Clinical sciences
- 3105 Genetics
- 11 Medical and Health Sciences
- 10 Technology
- 06 Biological Sciences